Related Experiment Videos
Does lidocaine protect the heart during coronary revascularisation?
1Department of Anaesthesia and Intensive Care, Tampere University Hospital, Finland.
Acta Anaesthesiologica Scandinavica
|October 17, 1998
Summary
Continuous lidocaine infusion did not significantly improve cardioprotection during coronary revascularization. This study found no statistically significant evidence to support routine lidocaine use in patients undergoing this procedure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Lidocaine is a primary antiarrhythmic for ventricular arrhythmias during myocardial infarction (MI) and open-heart surgery.
- Its cardioprotective effects are linked to cardiac sodium channel blockade.
- Previous studies explored lidocaine's role in reperfusion and revascularization.
Purpose of the Study:
- To investigate the contribution of continuous lidocaine infusion to cardioprotection.
- To assess lidocaine's efficacy during coronary revascularization with blood cardioplegia.
Main Methods:
- An open study involving 100 patients undergoing coronary revascularization with cold blood cardioplegia.
- A study group (n=50) received a 20-hour prophylactic lidocaine infusion starting with a bolus dose.
- A control group (n=50) did not receive lidocaine infusion. Serum troponin T and CK-MB levels were primary outcome measures.
Main Results:
- Serial measurements of Troponin T and CK-MB values were slightly lower in the lidocaine group.
- However, these differences did not reach statistical significance (P = 0.06 for Troponin T, P = 0.09 for CK-MB).
Conclusions:
- The study found no statistically significant evidence of improved cardioprotection with continuous lidocaine infusion.
- Lidocaine infusion cannot be recommended as a routine treatment during coronary revascularization based on these findings.